E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Paediatric HIV-1 Infection |
|
E.1.1.1 | Medical condition in easily understood language |
HIV-1 Infection in children |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine whether young people with chronic HIV infection taking lopinavir/ritonavir once daily as part of their anti-HIV therapy maintain the same level of suppression of the virus as those taking their therapy twice daily. |
|
E.2.2 | Secondary objectives of the trial |
-To compare the level of lopinavir in the blood when tablets are taken once or twice daily. -To compare the levels of lopinavir in the blood when half-strength tablets are taken accordingly to weight bands compared with existing data from studies on lopinavir soft gel capsules and oral solution. |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
A pharmacokinetic (PK) study will be performed. The first objective will be to confirm weight-based dosing recommendations by evaluating the PK of twice-daily half strength formulation tablets dosed on body weight and comparing to historical data of PK of soft gel capsules and oral solution respectively. The PK of once daily dosing in children will also be evaluated. The second objective of the PK study is to compare the PK of once daily dosing with twice daily dosing. |
|
E.3 | Principal inclusion criteria |
• Aged <18 years (up to 18th birthday) with confirmed HIV-1 infection • Weight ≥15 kg • Able to swallow tablets • Stable (i.e. CD4 not declining) on a combination antiretroviral regimen that has included lopinavir/ritonavir for at least 24 weeks • Taking lopinavir/ritonavir dosed twice-daily and be willing at the screening visit to change to tablet formulation (if not currently taking tablets) and to change the lopinavir/ritonavir dose to follow the recommended FDA dosing plan based on body weight bands as necessary; if participating in the PK study*, be willing at the screening visit to change to lopinavir/ritonavir half strength formulation tablets (100/25mg) only, dosed twice-daily and change the lopinavir/ritonavir dose to follow the recommended FDA dosing plan based on body weight bands as necessary • most recent HIV-1 RNA viral load <50 copies/ml, and viral suppression for the previous 24 weeks. Where viral suppression is defined as HIV-1 RNA <50 copies/ml, with the exception of a single measurement ≥50 but <400 copies/ml • Children and caregivers willing to participate in the PK study if they are among a minimum 16 children enrolled in each body weight band in the trial, including a second PK assessment if randomised to switch to once-daily lopinavir/ritonavir. • Parents/carers and children, where applicable, give informed written consent
* a minimum of 16 children per weight band will be entered into the PK study and must be willing to change to taking half-strength formulation lopinavir/ritonavir tablets (100/25mg) only, dosed according to the FDA recommended dosing plan based on their body weight, at the screening visit. Once it has been confirmed that evaluable PK data have been obtained for each weight band on twice- and once-daily dosing, it will no longer be necessary for children entering the trial to take half strength formulation lopinavir/ritonavir tablets only. |
|
E.4 | Principal exclusion criteria |
•children on an antiretroviral regimen that includes a NNRTI or any PI other than lopinavir/ritonavir •children who have previously failed virologically on a PI containing regimen (where virological failure is defined as two successive HIV-1 RNA results>1000 copies/ml (confirmed) more than 24 weeks after starting HAART, i.e changes for toxicity are not counted as failure) •acute illness •abnormal renal or liver function (grade 3 or above) •receiving concomitant therapy except for prophylaxis; Some treatments may be allowed, but must first be discussed with a trial medical expert •pregnancy or risk of pregnancy in females of child bearing potential |
|
E.5 End points |
E.5.1 | Primary end point(s) |
HIV-1 RNA ≥50 copies/ml (confirmed) at any of week 4, 8, 12, 24, 36 or 48.
For the PK sub study: AUC, Cmin and Cmax values of lopinavir after twice-daily dosing compared to historical adult and paediatric data. AUC, Cmin and Cmax values of lopinavir after once-daily and twice-daily dosing (in the same children)
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
HIV-1 RNA ≥50 copies/ml (confirmed) at any of week 4, 8, 12, 24, 36 or 48. |
|
E.5.2 | Secondary end point(s) |
•HIV-1 RNA <400/<50 copies/ml at 24 and 48 weeks •HIV-1 RNA ≥400 copies/ml at any of week 4, 8, 12, 24, 36 or 48 •number of HIV-1 mutations present at week 4, 8, 12, 24, 36 or 48 conferring resistance to drugs taken at randomisation or during the trial •change in CD4 (absolute and percentage) from baseline to 24 and 48 weeks •change in ART (defined as any change from the ART regimen at randomisation) •ART-related grade 3 or 4 clinical and laboratory adverse events •new CDC stage C diagnosis or death •child and family acceptability of and adherence to twice-daily lopinavir/ritonavir 100/25mg tablets dosed on body weight, over 48 weeks as assessed by patient/carer completed questionnaires •child and family acceptability of and adherence to once-daily compared to twice-daily dosing of lopinavir/ritonavir tablets, over 48 weeks as assessed by patient/carer completed questionnaires
Tertiary Outcomes: • Tanner Scale at 24 and 48 weeks |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
•HIV-1 RNA <400/<50 copies/ml at 24 and 48 weeks •HIV-1 RNA ≥400 copies/ml at any of week 4, 8, 12, 24, 36 or 48 •no. of HIV-1 mutations: week 4, 8, 12, 24, 36 or 48 conferring resistance to drugs taken at randomisation or during the trial •change in CD4 (absolute and percentage) from baseline to 24 and 48 weeks •change in ART (defined as any change from the ART regimen at randomisation) •child and family acceptability: twice-daily lopinavir/ritonavir 100/25mg tablets dosed on body weight, over 48 •child and family acceptability: once-daily compared to twice-daily dosing of lopinavir/ritonavir tablets, over 48
Tertiary Outcomes: • Tanner Scale at 24 and 48 weeks |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | Yes |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | Yes |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Once-daily dose of Lopinavir/ritonavir compared to twice-daily dose of Lopinavir/ritonavir |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 8 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 58 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Belgium |
Brazil |
France |
Germany |
Ireland |
Italy |
Netherlands |
Portugal |
Romania |
Spain |
Thailand |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The trial will be considered closed after the last patient to be enrolled reaches 48 weeks of follow-up. Participants will be able to continue on once daily Kaletra as long as they do not reach the viral load criteria for re-start of twice-daily dosing.
Cares are asked to give consent to further follow up of routine data at the end of the trial. If long term follow-up of the trial is indicated, ethical opinion will be sought.
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |